ARCHIVES

PFS Is A Benefit “In The Right Context,” Pazdur Says In Q&A On Avastin Approval.

This article is from The Cancer Letter archive.

Vol. 34 No. 08 | February 29, 2008

Download PDF Visit The Full Archive

Related Articles

NIH Director Varmus Names President of Sloan-Kettering, Succeeding Mark

October 15, 1999

ASCB Annual Awards, Honors.

January 7, 2000

Conference Level For NCI Is 5.4% Over FY 1990

November 2, 1990

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

Volasertib and LDAC Doubled Response in Older Patients

July 25, 2014

High-Dose Chemo Doesn’t Improve Survival In Small Cell Lung Cancer

April 25, 2008